Accuracy of Testosterone Concentrations in Compounded Testosterone Products

Journal of Sexual Medicine

Volumn 12, Issue 6, 2015, Pages 1381-1388

  Grober, Ethan D ^a   Garbens, Alaina ^a   Božović, Andrea ^b,c   Kulasingam, Vathany ^b,c   Fanipour, Majid ^a   Diamandis, Eleftherios P ^a,b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Compounding; Pharmacy Final Decision; Testosterone

Indexed keywords

TESTOSTERONE; GEL;

ANDROGEN DEFICIENCY; ANDROGEN THERAPY; ARTICLE; CONTROLLED STUDY; CREAM; DRUG BLOOD LEVEL; DRUG COST; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SYNTHESIS; GEL; GOOD MANUFACTURING PRACTICE; HUMAN; LIQUID CHROMATOGRAPHY; PHARMACY; PRESCRIPTION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; BLOOD; CANADA; EPIDEMIOLOGY; STANDARDS;

CANADA; DRUG COMPOUNDING; GELS; HUMANS; PHARMACIES; TESTOSTERONE;

EID: 84930376129     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12898     Document Type: Article

References (30)

1. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry HM 3rd. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000;49:1239-1242.
2. United Nations DoEaS. Affairs Population D World Population Prospects: The 2006 Revision, Highlights, Working Paper No. ESA/P/WP.202; 2007.
3. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM, Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536-2559.
4. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008;159:507-514.
5. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA 2006;295:1288-1299.
6. Biswas M, Hampton D, Newcombe RG, Rees DA. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf) 2012;76:665-673.
7. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Aznaouridis K, Rokkas K, Aggelis A, Synodinos A, Lazaros G, Stefanadis C. Plasma total testosterone and incident cardiovascular events in hypertensive patients. Am J Hypertens 2013;26:373-381.
8. Kamischke A, Kemper DE, Castel MA, Lüthke M, Rolf C, Behre HM, Magnussen H, Nieschlag E. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998;11:41-45.
9. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999;84:1966-1972.
10. Morales A, Bella AJ, Chun S, Lee J, Assimakopoulos P, Bebb R, Gottesman I, Alarie P, Dugré H, Elliott S. A practical guide to diagnosis, management and treatment of testosterone deficiency for Canadian physicians. Can Urol Assoc J 2010;4:269-275.
11. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013;169:725-733.
12. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-1665.
13. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, Volterrani M, Yellowlees A, Howell JD, Channer KS, TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828-837.
14. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009;30:726-733.
15. Handelsman DJ. Global trends in testosterone prescribing, 2000-2011: Expanding the spectrum of prescription drug misuse. Med J Aust 2013;199:548-551.
16. Compounding Pharmacies in the US Industry Market Research Report. IBIS World, Los Angeles, CA (PRWEB) May 21, 2012 Available at: http://www.prweb.com/releases/2012/5/prweb9521056.htm (accessed April 21, 2015).
17. The Association of Compounding Pharmacists of Canada. 2015. Available at: http://www.acpcrx.org/index.htm (accessed April 21, 2015).
18. Health Canada's policy on Manufacturing and Compounding Drug Products (POL-0051, 2009). 2009. Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/compli-conform/pol_0051-eng.pdf (accessed April 21, 2015).
19. United States Food and Drug Administration. Compounding Quality Act, Title I of the Drug Quality and Security Act. 2013. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/default.htm (accessed April 21, 2015).
20. United States Food and Drug Administration. Report: 2006 Limited FDA Survey of Compounded Drug Products. 2006. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/PharmacyCompounding/ucm204237.htm (accessed April 21, 2015).
21. A Review of the Oncology Under-Dosing Incident. A Report to the Ontario Minister of Health and Long-Term Care July 12, 2013. Available at: http://www.health.gov.on.ca/en/public/programs/cancer/drugsupply/docs/report_thiessen_oncology_under-dosing.pdf (accessed April 21, 2015).
22. Chen Y, Yazdanpanah M, Hoffman BR, Diamandis EP, Wong PY. Rapid determination of serum testosterone by liquid chromatography-isotope dilution tandem mass spectrometry and a split sample comparison with three automated immunoassays. Clin Biochem 2009;42:484-490.
23. Product Monograph-Androgel® Testosterone gel 1%. 2015. Abbott Labs Available at: http://www.abbott.ca/docs/ANDROGEL-PM-E.pdf (accessed April 21, 2015).
24. Product Monograph-Testim® Testosterone gel 1%. 2009. Paladin Labs, Available at: http://www.paladin-labs.com/our_products/PM_Testim_EN.pdf (accessed April 21, 2015).
25. Government of Canada, Justice Laws Website. Controlled Drugs and Substances Act, S.C. 1996, c.19. Amended November 6, 2012. Available at: http://laws-lois.justice.gc.ca/PDF/C-38.8.pdf (accessed April 21, 2015).
26. Farid A, Murdock FA Jr, Bonnett A, Mawhinney TP, Chance D, Waters JK, Hewett JE. Quality of intrathecal baclofen from different sources. PM R 2012;54:383-389.
27. Rood JM, Engels MJ, Ciarkowski SL, Wagenknecht LD, Dickinson CJ, Stevenson JG. Variability in compounding of oral liquids for pediatric patients: A patient safety concern. J Am Pharm Assoc 2014;54:383-389.
28. Kadi A, Francioni-Proffitt D, Hindle M, Soine W. Evaluation of basic compounding skills of pharmacy students. Am J Pharm Educ 2005;69:508-515.
29. Centre for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections. 2013. Available at: http://www.cdc.gov/hai/outbreaks/meningitis.html (accessed April 21, 2015).
30. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D 2013;13:1-8.